Compare T-Rex 2X Long MSTR Daily Target ETF (MSTU) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Long MSTR Daily Target ETF vs Repligen Corporation Common Stock — how do they compare? T-Rex 2X Long MSTR Daily Target ETF trades at $32.86 (market cap $790.58M), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 14.1× T-Rex 2X Long MSTR Daily Target ETF's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold T-Rex 2X Long MSTR Daily Target ETF for 19 Days and Repligen Corporation Common Stock for 0 Days on average.
| MSTU | RGEN | |
|---|---|---|
Market Cap | $790.58M | $11.14B |
Volume | 1,852,380 | 1,259,263 |
Sector | Leveraged / Inverse | Health |
52-Week High | $389.00 | $194.57 |
52-Week Low | $14.60 | $102.87 |
Typical Hold Time | 19 Days | 0 Days |
Enterprise Value | — | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTU trades at $38.54, down 0.57% with a bearish technical signal. The stock faces resistance at $40-$45 while finding support at $37-$33 levels. Recent corporate actions include a 10:1 reverse stock split effective August 24, 2026, and a $0.29 dividend declaration. Trading activity remains elevated as investors seek leveraged exposure to the underlying company amid market volatility.
The outlook remains cautious with technical indicators showing bearish momentum and limited fundamental data available. Key risks include the leveraged ETF structure's daily compounding effects and dependence on underlying stock performance. Investors should monitor for updated financial disclosures and analyst coverage to assess the fund's positioning and valuation metrics.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
